Bavencio (avelumab) + Axitinib

About Merck KGaA

Merck KGaA's mission is to advance science and technology to improve lives and solve pressing challenges. Its key achievements include building a leading oncology franchise with Bavencio, establishing MilliporeSigma as a dominant global supplier to the life science industry, and becoming a critical materials partner for the electronics sector. The company's strategy leverages its deep scientific expertise across its three interconnected pillars to capitalize on long-term trends in healthcare digitization, biopharma outsourcing, and technological miniaturization.

Therapeutic Areas